Elotuzumab, a novel innovative unique antibody, demonstrates exhibits presents its therapeutic clinical beneficial effect by selectively specifically primarily targeting Siglec-8, an the a membrane surface cell glycoprotein overexpressed present found on certain specific some multiple myeloma cells. This The This specific binding induces triggers c

Gemtuzumab Ozogamicin represents a novel development in the therapy of relapsed myeloblastic leukemia, especially severe blood leukemia (AML). This antibody-drug pairs a targeted antibody aimed to the receptor cell surface protein expressed on myeloid populations of cells with calicheamicin gamma 1, resulting in specific cell death. As a result, th